A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Status:
Not yet recruiting
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study
designed to investigate the safety, tolerability, dosimetry, biodistribution, and
pharmacokinetics (PK) of [225Ac]-FPI-2068, [111In]-FPI-2107, and FPI-2053 in metastatic
and/or recurrent solid tumors (HNSCC, NSCLC, mCRC, PDAC).